141 Spam-Free Article(s) Found
Article Searches
Array's Melanoma Combo Shows Positive Overall Survival Data http://www.zacks.com/stock/news/291687/arrays-melanoma-combo-shows-positive-overall-survival-data?cid=CS-ZC-FT-291687 Feb 07, 2018 - Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Here's Why Array BioPharma Inc. Is Rising Today https://www.fool.com/investing/2018/02/06/heres-why-array-biopharma-inc-is-rising-today.aspx?source=iedfolrf0000001 Feb 06, 2018 - The combination of better-than-expected quarterly results and upbeat clinical results put traders in a good mood.
Array BioPharma's (ARRY) CEO, Ron Squarer on Q2 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4143631-array-biopharmas-arry-ceo-ron-squarer-q2-2018-results-earnings-call-transcript?source=feed_all_articles Feb 06, 2018 - Array BioPharma Inc. (NASDAQ:ARRY) Q2 2018 Earnings Conference Call February 6, 2018 9:00 am ET Executives Ron Squarer - Chief Executive Officer Jason Haddock - Chief Financial Officer Andy Robbins -
ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List https://seekingalpha.com/article/4143537-roty-edition-1-volume-76-deal-market-selloffs-spring-cleaning-contenders-list?source=feed_all_articles Feb 06, 2018 - Recent market volatility (and how to approach it) is addressed below.February is off to a decidedly negative start for ROTY.Readers are encouraged to make their voices heard in my recent blog post if
Array BioPharma Inc. 2018 Q2 - Results - Earnings Call Slides https://seekingalpha.com/article/4143453-array-biopharma-inc-2018-q2-results-earnings-call-slides?source=feed_all_articles Feb 06, 2018 - The following slide deck was published by Array BioPharma Inc. in conjunction with their 2018 Q2 earnings call.
ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates https://seekingalpha.com/article/4142609-roty-edition-1-volume-75-future-roty-cascadian-acquired-updates?source=feed_all_articles Feb 02, 2018 - I encourage readers to check out my recent blog post which goes into detail regarding changes to Seeking Alpha and consequently to ROTY.The acquisition of Cascadian Therapeutics by Seattle Genetics is
3 Reasons Loop Capital Is Bullish On Arris International http://feeds.benzinga.com/~r/benzinga/~3/aPLQSzMkXlg/3-reasons-loop-capital-is-bullish-on-arris-internationa Jan 30, 2018 -

Shares of ARRIS International plc (NASDAQ: ARRS), a media entertainment and data communications solutions provider, lost more than 12 percent of its value over the past year and doesn't reflect the company's "robust growth opportunities" ahead, according to one Wall Street analyst.

Handelsinvest Investeringsforvaltning Buys MasTec Inc, Visteon Corp, Bank of the Ozarks Inc, ... http://www.gurufocus.com/news/632083/handelsinvest-investeringsforvaltning-buys-mastec-inc-visteon-corp-bank-of-the-ozarks-inc-sells-ipg-photonics-corp-cognex-corp-rollins-inc Jan 30, 2018 - Handelsinvest Investeringsforvaltning Buys MasTec Inc, Visteon Corp, Bank of the Ozarks Inc, Sells IPG Photonics Corp, Cognex Corp, Rollins Inc, Stocks: OZRK,TPIC,ARRY,NTES,NUAN,IMAX,MTZ,VC,KAR,SBRCY,POW, release date:Jan 30, 2018
ROTY Edition 1 Volume 72: Biotech Shines In January As We Manage Risk Appropriately https://seekingalpha.com/article/4139441-roty-edition-1-volume-72-biotech-shines-january-manage-risk-appropriately?source=feed_all_articles Jan 23, 2018 - The biotech sector is performing very well thus far in 2018, while the ROTY model account has about doubled the returns of the IBB. Several ROTY holdings are hitting new 52 week highs and I remind rea
Your Daily Pharma Scoop: Omeros' OMS721, Celgene To Acquire Juno, BioCryst And Idera To Merge https://seekingalpha.com/article/4139223-daily-pharma-scoop-omeros-oms721-celgene-acquire-juno-biocryst-idera-merge?source=feed_sector_healthcare Jan 23, 2018 - Omeros’ OMS721 got a positive opinion from EMA’s COMP for an orphan drug designation in Europe.Celgene will acquire Juno for $87 per share.BioCryst and Idera announced a merger.

Pages: 1234567891011...15

<<<Page 6>